Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for FF.MI and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FF.MI and 80,000+ other tickers.
See exactly how FF.MI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FF.MI and 80,000+ other tickers.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical offerings include items such as powders, granules, capsules, standard and film-coated tablets, effervescent granules, and hard gelatine capsules. For the nutraceutical market, the company produces soluble, effervescent, and chewable tablets, fast-melting/sublingual tablets, film-coated tablets, and hard gelatine capsules, alongside soluble and…
No recent news available.